NCT00307229已完成1 期
A Phase I Trial Investigating the Safety and Immunogenicity of an Adenovirus Encoding Rat HER-2 Administered Intradermally to Patients With Metastatic or Locally Recurrent Breast Cancer
Ontario Clinical Oncology Group (OCOG)2 个研究点 分布在 1 个国家目标入组 8 人开始时间: 2006年3月1日最近更新:
适应症
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 发起方
- 入组人数
- 8
- 试验地点
- 2
- 主要终点
- toxicity
研究概览
简要总结
To determine the maximum tolerated dose and/or maximum attainable dose of a vaccine consisting of adenovector expressing rat Her-2/neu in patients with metastatic or locally recurrent breast cancer.
研究设计
- 研究类型
- Interventional
- 分配方式
- Non Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •metastatic or locally recurrent breast cancer,
- •18 years of age or older,
- •Her-2/neu positive (3+ by immunohistochemistry or FISH +),
- •One of the following
- •currently receiving hormonal therapy or are candidates for such or,
- •being considered for trastuzumab or,
- •their cancer has progressed on trastuzumab
排除标准
- •Pregnant or lactating women.
- •Prior or concurrent malignancies except treated basal cell or squamous carcinoma of the skin or in situ cancer of the cervix or any other cancer treated and presumed cured more than five years prior to study entry.
- •Currently receiving chemotherapy, immunotherapy, adenoviral gene therapy or biological cancer therapy. [Note: concurrent hormonal therapy (tamoxifen,aromatase inhibitors, or megace) is permitted.].
- •Treatment with trastuzumab within 4 weeks prior to first dose of vaccine therapy.
- •Hemoglobin < 80 g/L or granulocytes < 1.5 x 109 /L or lymphocytes < 1.0 x 109 /L or platelets < 100 x 109 /L.
- •Baseline liver enzymes (AST or ALT) greater than 3 times upper limit of normal or greater than 5 times upper limit of normal if liver metastases present and/or bilirubin greater than 50 mmol.
- •CD4 cells < 0.5 x 109 /L
- •Patients with documented brain metastases.
- •Patients with any acute illness that would interfere with vaccination
- •Any patients requiring concurrent immunosuppressive therapy (e.g. corticosteroids).
- •Eastern Cooperative Oncology Group (ECOG) performance status of >
- •Patients with a life expectancy of less than 6 months.
- •Geographic inaccessibility which would preclude follow-up. Patients registered on the trial must be treated and followed at the Jewish General Hospital.
- •Failure to give written informed consent.
- •Baseline left ventricular ejection fraction (LVEF) < 55% by echocardiography or MUGA scan.
结局指标
主要结局
toxicity
时间窗: Weeks 4, 6, 7, 10, 14, 18, 22, 26
次要结局
- tumour response(Weeks 6, 18)
研究者
研究点 (2)
Loading locations...
相似试验
已完成
1 期
A Trial to Determine the Maximum Tolerated Dose and Evaluate the Safety and Pharmacokinetics of Docetaxel-PNP, Polymeric Nanoparticle Formulation of Docetaxel, in Subjects With Advanced Solid MalignanciesAdvanced Solid MalignanciesNCT01103791Samyang Biopharmaceuticals Corporation19
已完成
1 期
Study of Safety & Biological Activity of IP IMNN-001 (also Known As GEN-1) with Neoadjuvant Chemo in Ovarian CancerFallopian Tube CancerPrimary Peritoneal CancerEpithelial Ovarian CancerNCT02480374Imunon18
已完成
1 期
AST-021p Study in Advanced Solid TumorsAdvanced CancerNCT04864418Aston Sci. Inc.22
已完成
1 期
Safety Study of Increasing Doses of CKD-516 in Patients With Advanced Solid CancersUnspecified Adult Solid Tumor, Protocol SpecificNCT01560325Chong Kun Dang Pharmaceutical21
已完成
1 期
Safety Study of Increasing Doses of CKD-516 in Patients With Advanced Solid CancersUnspecified Adult Solid Tumor, Protocol SpecificNCT01028859Chong Kun Dang Pharmaceutical30